# CJC-1295 Ipamorelin FAQ: Common Questions, Cited Answers

> CJC-1295 Ipamorelin questions answered from the literature — selectivity, side effects, time-course, fat loss, FDA status, and the sermorelin and tesamorelin comparisons, each cited.

Direct answers to the questions readers most often ask, attributed to single-component and synergy studies.

## Is Ipamorelin stronger than Sermorelin?

They are not measured on the same axis. Ipamorelin's distinction is selectivity, not raw strength: it is the first selective GH secretagogue, not raising ACTH or cortisol above GHRH-stimulated levels even at more than 200 times the dose needed for half its GH effect, while matching GHRP-6's GH efficacy in swine [2]. Sermorelin is a short-acting GHRH peptide working through a different receptor entirely.

## Does Ipamorelin make you hungry / increase appetite?

It can, mechanistically: ipamorelin acts on the ghrelin (hunger) receptor, and increased appetite after dosing is among the most frequently reported community effects — generally described as milder than with GHRP-6. This is anecdotal, not clinical evidence. The class safety review's chief documented concern is metabolic — raised blood glucose from decreased insulin sensitivity — not appetite [6].

## Does Ipamorelin burn fat?

No controlled human trial shows ipamorelin burning fat. The closest cited evidence is for a different molecule, the GHRH analogue tesamorelin: a 2026 meta-analysis of five randomized trials found reduced visceral fat (−27.71 cm²) and liver fat (−4.28%) and increased lean mass (+1.42 kg) [7]. Community fat-loss reports for the stack are gradual, lifestyle-confounded, and anecdotal.

## What is CJC-1295 / Ipamorelin good for?

In documented terms, each component reliably raises growth hormone: a single dose of CJC-1295 (DAC) raised GH two- to ten-fold for six or more days and IGF-1 for nine to eleven days in healthy adults [1], and ipamorelin releases GH cleanly without stress-hormone activation [2]. Downstream day-to-day benefits people report — sleep, recovery — are anecdotal, not proven for the blend.

## What are the bad side effects of CJC-1295 and Ipamorelin?

Mechanistically expected effects of raising GH include fluid retention, carpal-tunnel-type tingling, joint aches, and raised blood glucose from reduced insulin sensitivity — the class's chief metabolic concern per a secretagogue safety review [6]. Community reports add injection-site reactions and a brief post-injection flush. The blend itself has no controlled-trial adverse-event record.

## How long do CJC-1295 and Ipamorelin take to work?

Pharmacologically, the hormone response is fast and long. A single subcutaneous dose of CJC-1295 (DAC) raised GH for six or more days and IGF-1 for nine to eleven days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. Ipamorelin's GH peak comes near 40 minutes post-dose [8]. Reported subjective effects like sleep are described within one to two weeks, anecdotally.

## How many mg of CJC-1295 and Ipamorelin should I take?

This site gives no human dose and no protocol. The literature records what was studied: 30 to 60 µg/kg subcutaneous for CJC-1295 (DAC) in human pharmacokinetic work [1], and rodent-only ipamorelin doses such as 100 µg/kg three times daily [11]. There is no validated human ipamorelin dose and no trial of the fixed combination. Dosing decisions are not addressed here.

## Does CJC-1295 raise testosterone?

The literature here concerns the GH/IGF-1 axis, not testosterone. A single dose of CJC-1295 (DAC) raised GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults [1]; no testosterone elevation is established for CJC-1295 in this record. Claims of a direct testosterone effect are not supported by the cited studies.

## Does Ipamorelin reduce belly fat?

No controlled human trial demonstrates ipamorelin reducing belly fat. The cited visceral-fat evidence belongs to the GHRH analogue tesamorelin, where a 2026 meta-analysis found a −27.71 cm² visceral-fat reduction across five randomized trials [7]. For ipamorelin specifically, belly-fat reduction is a community report, gradual and lifestyle-confounded — anecdotal, not clinical evidence.

## What are the downsides to CJC-1295 / Ipamorelin?

The genuine downsides are the untested fixed blend, mismatched pharmacokinetics (a days-long agent paired with an hours-long one) [1] [2], no FDA approval, unverified research-grade purity, and the class glucose signal [6]. Reported nuisances include water retention, post-injection flushing, and injection-site reactions. The honest summary: documented single-component pharmacology, undocumented combination safety.

## Which is better, Sermorelin or Ipamorelin?

There is no head-to-head trial, so "better" depends on the goal. Sermorelin is a short-acting GHRH peptide; ipamorelin is a selective ghrelin-receptor secretagogue [2] working through a different receptor. They are not substitutes for one another — in the combination, the CJC-1295 GHRH arm is the sermorelin-comparable piece, while ipamorelin adds a second, independent mechanism. Neither is FDA-approved as used here.

## Can you take both Sermorelin and Ipamorelin together?

The general principle that a GHRH peptide and a GHRP can be combined is well established: in normal men, submaximal GHRP doses combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms [3]. That said, this site describes the published synergy, not a protocol — it does not advise combining or administering any compounds, and no trial of that specific pairing exists.

## Is Tesamorelin better than Ipamorelin?

They do different jobs and are not directly comparable. Tesamorelin is a GHRH analogue with strong controlled human body-composition data — a 2026 meta-analysis of five trials found reduced visceral and liver fat and increased lean mass [7]. Ipamorelin is a selective ghrelin-receptor secretagogue [2] with no comparable controlled human body-composition trial. "Better" depends entirely on which mechanism and endpoint are in question.

## Which is safer, Sermorelin or Ipamorelin?

No controlled head-to-head comparison exists, so safety cannot be ranked from the record. Both ultimately raise GH and therefore share the class signal — chiefly raised blood glucose from decreased insulin sensitivity, with long-term cancer and mortality data still needed [6]. Ipamorelin's selectivity (no stress-hormone activation) is a documented tolerability advantage over the older GHRPs [2], but that is a within-GHRP comparison, not a sermorelin one.

## What is CJC-1295 / Ipamorelin?

It is a research combination of two peptides: CJC-1295, a long-acting GHRH analogue (with DAC, an albumin-binding feature giving it a multi-day half-life [5]), and ipamorelin, the first selective GH secretagogue acting on the ghrelin receptor [2]. Together they push two independent switches on the pituitary to raise growth-hormone release. Neither is FDA-approved, and the fixed blend has no controlled-trial record.

## How much CJC-1295 / Ipamorelin should I take?

No human dosing is provided here. The published record contains research-context amounts only — for example, 30 to 60 µg/kg subcutaneous for CJC-1295 (DAC) in human PK studies [1], and rodent-only ipamorelin dosing [9] [11]. There is no validated human ipamorelin dose and no studied protocol for the combination, so this question is not answered with a number.

## Is CJC-1295 / Ipamorelin safe?

There is no controlled human safety study of the fixed blend, so its safety is uncharacterized. The single components and their class were judged generally well tolerated in a secretagogue review, with raised blood glucose the chief concern and long-term cancer and mortality data still needed [6], and ipamorelin shows a clean selectivity profile [2]. Unverified purity and self-administration add further unstudied risk.

## Does CJC-1295 / Ipamorelin work?

Each component demonstrably raises growth hormone: CJC-1295 (DAC) raised GH two- to ten-fold for six or more days and IGF-1 for nine to eleven days in healthy adults [1], and ipamorelin reliably releases GH [2]. Whether the *combination* produces the downstream day-to-day benefits people seek is not established by any controlled trial — those outcomes are extrapolated and anecdotal.

## Is Ipamorelin FDA approved?

No. Ipamorelin is not approved by the FDA for any indication and is sold only as a research chemical, as is CJC-1295. A secretagogue safety review notes the class is generally well tolerated but emphasizes that long-term and large-population safety data remain lacking [6]. The fixed combination likewise holds no approval and has never been studied in a controlled human trial.

## How to reconstitute CJC-1295 / Ipamorelin (5mg)?

This site does not provide reconstitution instructions. In a laboratory-handling context, lyophilized peptide is reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol), kept refrigerated at 2 to 8 °C, and protected from agitation and freeze-thaw because aqueous peptide degrades over weeks via deamidation. That is descriptive handling information for completeness, not a preparation protocol for use.

## Where to inject CJC-1295 / Ipamorelin?

No injection instruction is given here. The literature records subcutaneous administration as the dominant route in the human CJC-1295 pharmacokinetic work [1] and most rodent ipamorelin studies, with intravenous and intranasal routes also studied [8]. Those are records of how studies were conducted, not directions for administering anything to a person.

## Can I take CJC-1295 / Ipamorelin in the morning?

Timing is a dosing decision this site does not make. Mechanistically, the long-acting CJC-1295 (DAC) sustains GH and IGF-1 for days regardless of time of day [1], while ipamorelin produces a short pulse peaking near 40 minutes [8]; community accounts often favor a pre-bed pulse to align with sleep, but that is anecdotal preference, not a studied schedule, and no protocol is endorsed here.

---

A printed-style monograph of the published CJC-1295 and ipamorelin record — every claim attributed to a single-component or synergy study, the fixed blend openly noted as never trialed; no clinic, no prescription, and nothing here dosed or dispensed.